Agenix antibody in US diagnostic test
Thursday, 17 February, 2005
AGEN Biomedical, a subsidiary of Brisbane-based biotech Agenix (ASX: AGX), is set to receive royalties from a newly launched test developed by US diagnostics company Biosite that uses AGEN's D-Dimer antibody.
Biosite's Triage D-Dimer diagnostic is a point-of-care diagnostic for the assessment and evaluation of patients suspected of having thromboembolic events including pulmonary embolism and deep vein thrombosis. The ELISA-based test measures five biomarkers including D-Dimer, and provides results within 15 minutes. AGEN licensed the D-Dimer antibody and associated IP to Biosite in November 2003.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
